Regeneron Pharmaceuticals Profit Margin

As of the most recent data (September 2026), REGN shows a profit margin of 28.51%. That compares with 32.13% in the prior-year period — down 11.3% year over year. That is above the Healthcare sector average of 19.13%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, REGN's profit margin is now 28.51% (was 32.13%) — a 11.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Regeneron Pharmaceuticals is outperforming or lagging.

The Healthcare sector average profit margin is about 19.13%. Regeneron Pharmaceuticals is at 28.51%, which is higher that average. That is roughly 49.0% above the sector mean. Use the comparison chart on this page to see how REGN stacks up against individual peers as well.

That compares with 32.13% in the prior-year period — down 11.3% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Regeneron Pharmaceuticals with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Regeneron Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 28.51%) with ownership activity and broader fundamentals.